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Cell therapy is the most advanced treatment of the cerebral ischemia, nowadays. Herein, we discuss the neuroprotective effects
of bone marrow mesenchymal stem cells (BMSCs) on rat hippocampal cells following intravenous injection of these cells in
an ischemia-reperfusion model. Adult male Wistar rats were divided into 5 groups: control, sham (surgery without blockage of
common carotid arteries), ischemia (common carotid arteries were blocked for 30min prior to reperfusion), vehicle (7 days after
ischemia PBS was injected via the tail vein), and treatment (injections of BMSC into the tail veins 7 days after ischemia). We
performed neuromuscular and vestibulomotor function tests to assess behavioral function and, finally, brains were subjected to
hematoxylin and eosin (H&E), anti-Brdu immunohistochemistry, and TUNEL staining. The ischemia group had severe apoptosis.
The group treated with BMSCs had a lower mortality rate and also had significant improvement in functional recovery (𝑃 < 0.001).
Ischemia-reperfusion for 30min causes damage and extensive neuronal death in the hippocampus, especially in CA1 and CA3
regions, leading to several functional and neurological deficits. In conclusion, intravenous injection of BMSCs can significantly
decrease the number of apoptotic neurons and significantly improve functional recovery, which may be a beneficial treatment
method for ischemic injuries.
1. Introduction
Worldwide, cerebral ischemia is one of the leading causes of
long-term disability, morbidity, and death [1, 2]. Reperfusion
following cerebral ischemia induces neuroinflammation and
excessive production of reactive oxygen species (ROS) [3,
4]. Under physiological conditions a homeostatic balance
between the formation of oxygen-free radicals and their
removal by endogenous scavengers exists [5]. During cerebral
ischemia, reduction of glucose and oxygen transport to the
brain leads to the generation of free radicals which damage
lipids, DNA, and proteins, in addition to inflammation and
breakdown of the blood-brain barrier (BBB), resulting in cell
death [6–8].
Cerebral ischemia can lead to sensory, motor, cognition,
and spatial learning disorders depending upon the location
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of the ischemic event [9–11]. Motor disorders associated with
cerebral ischemia lead to disabilities that affect quality of life
[12]. The hippocampus is one of the first areas of the brain
affected by neurodegenerative diseases and injuries attributed
to cerebral ischemia. The pyramidal neurons of the CA1 area
of the hippocampus are themost sensitive neurons to hypoxia
and subsequent death during ischemic conditions [13–15].
In animalmodels, it has been proved that the ischemia has
injury mechanisms, including excitotoxicity, mitochondrial
dysfunction, and oxidative stress. On the way to protect
cells from cerebral ischemia, molecular chaperones or stress
proteins and some antiapoptoticmembers of the BCL2 family
of apoptosis regulatory proteins can protect mitochondrial
function, reducing oxidative stress [16–18].
Currently, only a few effective clinical therapies exist for
cerebral ischemia that lead to complete functional recov-
ery [19]. Recently, stem cell-based therapy has provided a
therapeutic tool for tissue repair and functional recovery in
neurological diseases and cerebral ischemia [20–22]. Stem
cells have the capacity of unlimited self-renewal and give
rise to differentiated cells from various cell lineages [23–25].
They are classified according to origin as embryonic, fetal, or
adult stem cells. Embryonic stem cells (ESCs) have restricted
availability and form teratomas after transplantation. Due
to ethical concerns, their application is limited [26, 27].
Among the stem cells, bone marrow mesenchymal stem
cells (BMSCs) have greater potential use in the treatment
of neurological disorders. These cells can be easily obtained
from patients without ethical or immunological problems
and can be produced in large numbers under in vitro
conditions [28, 29].
Several studies have suggested that BMSCs can migrate
to the injury site in the brain and differentiate into neurons
and glial cells [30]. Previous studies have mainly focused
on molecular and histological aspects of cerebral ischemia,
rather than behavioral consequences. However, behavioral
tasks are suitable tools for investigating the consequences
of cerebral ischemia. The present study investigates the
histopathological and behavioral effects of intravenously
transplanted BMSCs in a rat experimental model of cerebral
ischemia-reperfusion.
2. Methods and Materials
2.1. Animals. Adult male Wistar rats (𝑛 = 40) that weighed
250–300 g were obtained from the Animal House of the
Faculty of Medicine at Urmia University of Medical Sciences,
Urmia, Iran. Animals were maintained at 21 ± 1∘C (50 ±
10% humidity) on a 12 h light/12 h dark cycle with access
to water and food ad libitum. Animal care and the general
protocols for animal use were approved by the Animal Ethics
Community at Urmia University of Medical Sciences.
2.2. Experimental Design. We randomly divided the rats into
5 groups (𝑛 = 8) as follows: (1) control (intact) where the
animals underwent no ischemia or treatment; (2) sham in
which the animals underwent surgery without blockage of
the common carotid arteries; (3) ischemia in which bilateral
common carotid arteries were blocked for 30 minutes in
order to induce ischemia; (4) vehicle in which the rats
received 30 𝜇L phosphate-buffered saline (PBS) injected into
their tail veins 7 days after ischemia; and (5) treatment in
which the animals received BMSCs (1 × 106 in a 30 𝜇L
suspension) injected into their tail veins 7 days after ischemia.
2.3. Experimental Model of Cerebral Ischemia-Reperfusion.
We used a modified method of Jingtao et al. [31] to
induce cerebral ischemia-reperfusion. The animals were
anesthetized with ketamine (80mg/kg, Daroopakhsh, Iran)
and xylazine (10mg/kg, Daroopakhsh, Iran). The rats were
then placed in the supine position on an operating table
and covered with a warming blanket. Each animal’s body
temperature was controlled with a temperature control unit
during surgery.
After shaving and prepping with Betadine, a midline
incision was made that exposed both common carotid arter-
ies. Dissection was made between sternocleidomastoid and
sternohyoid muscles parallel to the trachea. Each common
carotid artery was freed from its adventitial sheath and
carefully separated from the vagus nerve. For induction of
ischemia, both common carotid arteries were occluded using
microaneurysm clamps for 30min followed by reperfusion.
The skin was stitched with silk suture.
2.4. Isolation and Culture of Bone MarrowMesenchymal Stem
Cells (BMSCs). Bone marrow was isolated in sterile condi-
tions from 8-week-old male Sprague Dawley rats (weights:
250–300 g) as described in detail by Azizi et al. [32]. Briefly
the rats were given an overdose of pentobarbital after which
their tibia and femurs were excised. Both ends of each
bone were cut and the marrow was aspirated with 5mL
DMEM(Sigma-Aldrich) and a 25-gauge needle.The resultant
suspension was centrifuged at 800 rpm for 5min and the
supernatant was removed. Subsequently, the marrow cells
were suspended in 10mL of DMEM supplemented with 10%
fetal bovine serum (FBS), 2mL glutamine, 100U/mL peni-
cillin (Sigma-Aldrich), and 100U/mL streptomycin (Sigma-
Aldrich).
After 48 h, the nonadherent BMSCs were removed by
replacing the medium. When 80% confluency was reached,
cells were detached and harvested after a 5min exposure to
0.25% trypsin/1mM EDTA (Sigma-Aldrich, USA) at 37∘C.
Cells were subsequently passaged into four subcultures for
further incubation. Various stages of cultured bone marrow
mesenchymal stem cells (BMSCs) have been shown in Fig-
ure 1.
2.5. Labeling of BMSCs and Cell Transplantation Procedure.
The cells were labeled with a 3 𝜇g/mL bromodeoxyuridine
(Brdu) solution added to the incubation medium 72 h prior
to transplantation [33].
2.6. Cell Transplantation Procedure. The 8 animals in group 5
(treatment) were anesthetized with ketamine (80mg/kg) and
xylazine (10mg/kg) at 7 days after ischemia. Approximately
1.0 × 106passage 3 BMSCs suspended in 30𝜇L PBS were
intravenously given into the rats’ tail veins over a 5-min
period. The vehicle group only received an infusion of 1mL
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Figure 1: Various stages of cultured bone marrow stromal cells. Bone marrow stromal cell morphology in the early (a), middle (b), and late
(c) subculture stages.
PBS injected into their tail veins. Immunosuppressant was
not used for any animal in this study.
2.7. Immunohistochemical Analyses. At 12 days after ischemia,
the rats were deeply anesthetized with sodium pentobarbital
(100mg/kg, IP) and then transcardially perfused with 4%
paraformaldehyde in 0.1M phosphate buffer (pH 7.3). After
transcranial perfusion, the animals’ brains were removed
and postfixed in 4% paraformaldehyde for one week. Next,
we processed the tissues and a series of adjacent 5 𝜇m
thick sections were cut from paraffin blocks in the coronal
plane. Immunohistochemical staining was used to detect the
distribution of transplanted BMSCs in the hippocampus,
as follows: deparaffinization of samples in xylol (Merck,
Germany), hydration in a graded alcohol series (100, 96, 80,
and 70%), incubation in 50% formamide (Merck, Germany),
incubation in 2x standard sodium citrate (SSC, Merck,
Germany) for 2 h at 65∘C, incubation in 2N HCl (Merck,
Germany) for 30min at 37∘C, rinse in 0.1 N boric acid
(Merck, Germany, pH 8.5) for 10min, followed by a PBS
wash, incubation with mouse anti-Brdu antibody (Sigma,
Germany) overnight at 4∘C, rinse in PBS (3 times for 10min),
incubation with secondary antibody conjugated with horse
radish peroxidase (goat anti-mouse IgG) (Sigma, Germany)
for 2 h, and incubation with diaminobenzidine tetrachloride
hydrate (DAB, Sigma, Germany) for 5min, after which the
slides were counterstained with hematoxylin, mounted, and
inspected under a light microscope.
2.8. Terminal Deoxynucleotidyl Transferase-Mediated dUTP
end Labeling (TUNEL). Apoptosis was determined by
terminal deoxynucleotidyl transferase-mediated dUTP end
labeling (TUNEL) which detects the DNA fragments of
apoptotic cells. TUNEL staining was performed with the In
Situ Cell Death Detection Kit (Roche Molecular Chemical,
cat. number 11684817910). Briefly, the sections were dewaxed
and rehydrated in xylol (Sigma, Germany) and a graded
series of 100%, 90%, 80%, and 70% ethanol. Endogenous
peroxidase activity was blocked by incubating with 0.3%
H
2
O
2
in methanol for 30min. For permeabilization of tissue,
the sections were incubated with 20𝜇g/mL proteinase K
(Roche, Germany) in 10mM Tris HCl (pH 7.5) for 10min
at room temperature. Then, the sections were incubated
in 50𝜇L of TUNEL solution (In Situ Cell Death Detection
Kit, Roche, Germany) for 1 h at 37∘C. After incubation
with converter POD, HRP for 1 h at 37∘C, the sections
were incubated with DAB (Sigma, Germany) chromogen at
37∘C. Cells were counterstained with hematoxylin (Sigma,
Germany) for 20 s. Sections were dehydrated in a graded
series of 70%, 80%, 90%, and 100% ethanol and cleared in
xylol for 15min. After mounting the sections were examined
by a light microscope.
2.9. Cell Counting and Apoptotic Index Determination. We
counted the numbers of apoptotic cells by randomly selecting
20 microscopic fields in the hippocampal CA1 and CA3
areas. Apoptotic pyramidal neurons were counted at 40x
magnification after which themean number of apoptotic cells
in the CA1 and CA3 areas was calculated. The total numbers
of cells in each field were counted and the mean number was
calculated.We determined the apoptotic index for each group
as follows:
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Figure 2: Immunohistochemical findings. (a) Treatment group. Intravenously transplanted bone marrow stromal cells 7 days after ischemia
have migrated to the hippocampal area around the injured site. The arrows indicate Brdu-positive bone marrow stromal cells. (b) Vehicle
group which received PBS 7 days after ischemia. There is no Brdu-positive bone marrow stromal cells.
Apoptotic index = Number of apoptotic cells
total number of cells
× 100. (1)
2.10. Histopathological Assessment. A number of the 5-𝜇m
prepared sections were used for histopathological assess-
ment. Hematoxylin and eosin (H&E) stained sections were
studied under a light microscope (400x) in order to eval-
uate the presence of necrosis and neuronal deficits such as
acidophilic and triangular shaped neurons, condensed and
pyknotic nuclei, and vacuolization.
2.11. Behavioral Examination. At three days before surgery,
the animals underwent daily training to assess neuromuscu-
lar and vestibulomotor functions. A total score was calculated
for each rat. According to these tests, animals with higher
scores had more deficits.
2.12. Neuromuscular Function. This test consisted of 6 sub-
tests: forelimb flexion, twisting, resistance to lateral push,
circling, hind limb placement, and inverted angle board
gripping. The subtests and their scoring method have been
carried out as described by Alexis et al. [34].
For forelimb flexion, a normal rat will extend both
forelimbs toward the surface when it is held by the tail
above a flat surface whereas infarcted animals will flex the
paralytic forelimb. The degrees of flexion vary from mild
wrist flexion and shoulder abduction to severe flexion of
the entire forelimb. Torso twisting in a normal rat involves
extension of the entire body toward the surface when held
by the tail above a flat surface. The infected rats showed
rotational behavior (body rotation) which was varied from
mild twisting of the body to severe body movement which
brings the head and forelimbs near the hind limbs. Twisting
happens usually toward the injured and paralytic side. In
the lateral push test the normal animal is held behind the
shoulders and pushed to the left or right side. A normal
rat shows equal resistance whereas the infarcted rat when
pushed toward the contralateral side will show no resistance
or a weaker resistance. During circling, the normal gate rats
normally do not circle. However infarcted rats often circle
toward the contralateral side. A normal rat during the hind
limb placement test will immediately return its hind limb
to the surface from which it has been removed; however
infarcted rats show a delay in placement or no placement of
the hind limb. In the inverted angle board test, the normal
rat can be trained to turn 180 degrees and move to the top of
the angled board. Infarcted rats cannot turn andmove up the
board.
2.13. Vestibulomotor Function (Beam Balance). This test
assesses cortical motor deficits. The test and its scoring
method have been performed according to Alexis et al. [34]
and Petullo et al. [35]. Briefly, the animal was positioned
on a beam of 3/4 inches’ width, 10 inches’ length that was
suspended 1 foot above a table top. A normal animal should
maintain steady posture with all limbs on top of the beam for
60 s.
2.14. Statistical Analysis. Statistical analysis was performed
using SPSS 17.0 software. The statistical differences between
different groups were evaluated with one-way analysis of
variance (ANOVA) followed by the Tukey test for mul-
tiple pairwise examinations. A value of 𝑃 < 0.05 was
considered statistically significant. According to the results
of the Kolmogorov-Smirnov test, the data for behavioral
assessments lacked normal distribution. Therefore the non-
parametric Kruskal-Wallis and Mann–Whitney tests were
used for statistical analyses.
3. Results
3.1. Immunohistochemistry Findings. Passage-3 BMSCs were
transplanted into the rats. Three days before transplantation,
the cells were labeled with Brdu (Sigma, Germany). After
transcardial perfusion, we prepared 5 𝜇m paraffin sections
in order to detect the BMSCs. The sections were stained
with anti-Brdu antibody (Sigma, Germany) according to
the immunohistochemistry kit instructions. Immunohisto-
chemistry findings confirmed the presence and viability of
transplanted cells at the area of lesion (hippocampus). The
implanted BMSCs survived at the injury site (hippocampus).
Lightmicroscopy (Figure 2) showed that intravenously trans-
planted Brdu-positive BMSCs survived and migrated to the
injured sites (CA1, CA3 areas of hippocampus).
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Figure 3: TUNEL reaction. (a) Control group with the lowest number of TUNEL positive (apoptotic) cells. (b) Ischemia group with the
highest number of TUNEL positive (apoptotic) cells. (c) Treatment group with fewer TUNEL positive (apoptotic) cells compared to the
ischemia group. The arrows show TUNEL positive cells (brown).
3.2. TUNEL Staining. Weused TUNEL staining to determine
the number of apoptotic cells in the CA1 and CA3 areas of
the hippocampus (Figure 3). The mean numbers of TUNEL
positive cells were as follows: 7.05 ± 2.982 (control), 8.25 ±
2.693 (sham), 20.45±10.308 (ischemia), 20.15±9.67 (vehicle),
and 10.0 ± 3.974 (treatment).The percent of TUNEL positive
(apoptotic) cells were as follows: control (15.44%), ischemia
(43.37%), treatment (23.61%), sham (17.92%), and vehicle
(43.29%). The control group had the lowest and ischemia
group had the highest numbers of apoptotic cells. The
treatment group had fewer apoptotic cells than the ischemia
group.
A significant difference existed in the number of TUNEL
positive cells between the control and ischemia groups (𝑃 =
0.000, Figure 4).Therewas a statistically significant difference
in the number of TUNEL positive cells between the ischemia
and treatment groups (𝑃 = 0.000, Figure 4).
3.3. Apoptotic Index Determination. The apoptotic index has
been determined for each group as (1).
In results, the apoptotic index was 43.37% (ischemia),
43.29% (vehicle), 23.61% (treatment), 17.92% (sham), and
15.44% (control). The apoptotic index in the treatment group
was less than the ischemia group (Figure 5).
3.4. Histopathological Evaluation. Histopathological assess-
ment showed that the control group neurons and neural
tissue were intact and had normal morphology (Figure 6(a)).
These cells had integrity and regular structure in the cerebral
tissue. The pyramidal cells had round nuclei, prominent
nucleolus, and clear cytoplasm. The ischemia group had
numerous pyramidal cells with pyknotic nuclei, lack of
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Figure 4: The mean number of TUNEL positive cells in the study
groups. The ischemia group had the greatest number of TUNEL
positive cells. There was a significant difference (shown with ∗) in
the numbers of apoptotic cells between the ischemia and control
groups (𝑃 = 0.000).
nucleolus, and hyperchromatic cytoplasm compared to cells
of the control group (Figure 6(b)). In the BMSC treatment
group, we observed considerably decreased numbers of cells
with pyknotic nuclei, lack of nucleolus, and hyperchromatic
cytoplasm compared to the ischemia group (Figure 6(c)).
3.5. Behavioral Examination
3.5.1. Effect of BoneMarrowMesenchymal StemCells (BMSCs)
on Neuromuscular Function. The neuromuscular function
test consisted of 6 subtests: forelimb flexion, twisting, resis-
tance to lateral push, circling, hind limb placement, and
6 Behavioural Neurology
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Figure 5: Apoptotic index in different groups. The results revealed
that this index was less in the treatment group compared to the
ischemia group (shown with ∗).
inverted angle board gripping. The details of these tests are
explained in Section 2.12. In this study, we have graded the
severity and degrees of neuromuscular function according
to Table 1. Neuromuscular function test assessed neuro-
muscular cortical deficits. Animals with higher scores have
more deficits, which means that higher scores indicate poor
outcome and lower scores indicate favorable outcome.
In results, there was a significant increase (𝑃 < 0.001) in
neuromuscular function test scores in the ischemia (6.56) and
vehicle (6.43) groups compared to the control (0.0) group.
The BMSC treatment group showed significant improve-
ment (3.12) in neuromuscular function compared with the
ischemia and vehicle groups (𝑃 < 0.001) (Figure 7).
3.5.2. Effect of BoneMarrowMesenchymal StemCells (BMSCs)
on Vestibulomotor Function. The vestibulomotor function
test assesses motor cortical deficits. Briefly the animals were
positioned on a beam of 3/4 inches’ width, 10 inches’ length
that was suspended 1 foot above a table top. A normal animal
should maintain a steady posture with all limbs on top of the
beam for 60 s. The severity and degrees of vestibulomotor
function were graded according to Table 2. Animals with
higher scores havemore deficits; in otherwords, higher scores
indicate poor outcome and lower scores indicate favorable
outcome.
In this study there was a significant increase in vestibu-
lomotor function score in the ischemia (3.25) and vehicle
(3.00) groups (𝑃 < 0.001) compared with the control (0.0)
group.The treatment group showed significant improvement
(1.12) in vestibulomotor function comparedwith the ischemia
group (𝑃 < 0.001, Figure 8).
4. Discussion
This study showed that intravenous transplantation of
BMSCs one week following an ischemia-reperfusion injury
decreased the apoptosis level of pyramidal neurons in theCA1
and CA3 areas of the hippocampus and improved functional
recovery. According to similar studies in the field of cerebral
ischemia, the treatment processes (especially with stem cells)
Table 1: Clinical scoring criteria (neuromuscular function).
Criteria Score Description
Forelimb flexion
0.0 No flexion
0.5 Mild
1.0 Moderate to severe
Torso twisting
0.0 No flexion
0.5 Mild
1.0 Moderate to severe
Lateral push
0.0 Equal resistances
0.5 Weak resistance
1.0 No resistance
Hindlimb placement
0.0 Immediately replaces
0.5 Delay in replacing
1.0 No replacement
Forelimb placement
0.0 Immediate replacement
0.5 Delay in replacing
1.0 No replacement
Inclined board
0.0 Turning 180 and thenreplacement
0.5 Able to stay up but not go to top
1.0 Tries to stay up but eventuallyslides down
1.5 Tries to stay up but immediatelyslides down
2.0 Not able to hold body up at all,immediately
Mobility
0.0 Normal
1.0 Spontaneous movement to move
1.5 Needs stimulus to move
2.0 Unable to walk
Maximum score 9.0
Table 2: Clinicl scoring criteria.
Vestibular
function Score Description
Balance beam
0.0 Balances with all 4 paws on top of the beam
1.0 Puts paws on side of beam or wavers
2.0 1 or 2 limbs slip off beam
3.0 3 limbs slip off beam
4.0 Attempts to balance but falls off
5.0 Animal drapes on beam then falls
6.0 Falls without attempting to balance
Maximum
score 6.0
are begun 7 days after ischemia induction. Researchers
believe that, during the first week after cerebral ischemia,
there is a collection of toxins and glutamate neurotransmitter
and free radicals in the injured area of the brain and after
7 days these toxins are removed and the area is prepared
Behavioural Neurology 7
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Figure 6: Histopathological assessment. (a) Control group neurons have an integrity and regular structure with normal morphology, round
nuclei, prominent nucleolus, and clear cytoplasm. (b) Ischemia group neurons have numerous pyramidal cells with pyknotic nuclei and lack
of nucleolus and hyperchromatic cytoplasm. (c) Treatment group have considerably decreased numbers of cells with pyknotic nuclei and lack
of nucleolus and hyperchromatic cytoplasm compared to the ischemia group (thin arrows indicate normal cells and thick arrows indicate
apoptotic cells).
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Figure 7: Effects of bonemarrowmesenchymal stem cells (BMSCs)
on neuromuscular function in rats after cerebral ischemia. Signifi-
cant difference with treatment group (𝑃 < 0.05) (shown with ∗).
to receive any new treatment (stem cells, growth factors,
neurotrophins, etc.) [36, 37].
As is showed in the results, the intravenous transplanta-
tion of BMSCs one week following an ischemia-reperfusion
injury decreased the apoptosis level of pyramidal neurons in
the CA1 and CA3 areas of the hippocampus and improved
functional recovery. In addition, the results of BMSCs culture
(Figure 1) and labeling with Brdu immunohistochemistry
showed that Brdu-positive BMSCs survived and migrated
to the injury site (hippocampus) (Figure 2). Moreover, the
results of TUNEL staining for determination of apoptotic
cells following the ischemic injury (Figure 3) showed that the
mean number of TUNEL positive cells in the ischemia group
was the highest and the control group had the lowest number
of TUNEL positive cells and there was a significant difference
in the number of apoptotic cells between the ischemia
and control groups (𝑃 = 0.000, Figure 4). The apoptotic
index was lower in the treatment group compared to the
ischemia group (Figure 5). Finally, these results indicated that
BMSCs injection after ischemia-reperfusion led to survival of
hippocampal cells and reduction of apoptosis in these cells.
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Figure 8: Effects of bonemarrowmesenchymal stem cells (BMSCs)
on vestibulomotor function in rats after cerebral ischemia. Signifi-
cant difference with treatment group (𝑃 < 0.05) (shown with ∗).
The abovementioned findings indicated that the
ischemia-reperfusion model in which the bilateral common
carotid arteries were occluded for 30min and then reperfused
was a valid experimental model. The majority of apoptotic
cells were observed in the ischemia group, which confirmed
that this model could cause apoptosis in the highest number
of hippocampal cells. A significant reduction was observed
in the number of apoptotic cells in the treatment group
compared to the ischemia group. Additionally, a statistically
significant difference existed in the number of apoptotic cells
between the treatment and ischemia groups (𝑃 = 0.000).
In histopathological assessment results it is clear that
the control group neurons had normal morphology, round
nuclei, prominent nucleolus, and clear cytoplasm, while the
ischemia group had many pyramidal cells with pyknotic
nuclei, lack of nucleolus, and hyperchromatic cytoplasm.
The BMSC treatment group had a significantly decreased
number of cells with pyknotic nuclei, lack of nucleolus,
and hyperchromatic cytoplasm compared to the ischemia
group (Figures 6(a)–6(c)). These findings indicated that
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administration of BMSCs after ischemia-reperfusion reduced
the number of apoptotic cells.
The results of behavioral examination for evaluating
the sensorimotor function in the three areas, neuromuscu-
lar, vestibulomotor, and complex neuromotor, displayed a
decrease in the neuromuscular function score in the BMSC
treatment group compared to the ischemia group. This
result indicated a significant improvement (𝑃 < 0.001) in
neuromuscular function in the treatment group. In addition,
the results of vestibulomotor function and complex neuro-
motor function showed a decrease in scores of these tests
in the treatment group compared to the ischemia group.
These outcomes point out the significant improvement (𝑃 <
0.01) in vestibulomotor function and complex neuromotor
function in the treatment group. Finally, it can be concluded
in behavioral examinations that the intravenous injection
of BMSCs after ischemia-reperfusion significantly improved
functional recovery.
A number of researchers believe that BMSCs secrete
numerous growth factors [38], neurotrophic factors [39], and
brain natriuretic peptides which reduce neuronal apoptosis
[40]. On the other hand, some scientists explain that BMSCs
are multipotent cells capable of differentiating into neurons
and glial cells in vitro [41] and in vivo [42]; hence these
neurons and glial cells can replace damaged cells [43],
regenerate injured tissue, and promote functional recovery.
Mahmood et al. studied an experimental model of trau-
matic brain injury. They injected BMSCs intravenously and
reported that these cells migrated to the animals’ brains and
improved functional recovery [44]. They measured nerve
growth factor (NGF), brain derived neurotrophic factor
(BDNF), and fibroblast growth factor 𝛽 (bFGF) and con-
cluded that these factors might improve functional recovery
[45]. Crigler et al. reported that injected BMSCs secreted
neurotrophins, growth factors, and cytokines, which caused
cell proliferation, survival, and differentiation [46]. Chen et
al. demonstrated that BMSCs secreted NGF, BDNF, glial cell
derived neurotrophic factor (GDNF), neurotrophin 3 (NT3),
bFGF, vascular endothelial growth factor (VEGF), hepatocyte
growth factor (HGF), and ciliary neurotrophic factor (CNTF)
[47].
Nicaise et al. transplanted BMSCs in an experimen-
tal amyotrophic lateral sclerosis (ALS) model. Their study
showed that BMSCs expressed NGF, FGF2, and insulin-
like growth factor (IGF). They concluded that BMSCs with
expression of growth factors caused neurons to survive in
the brain [48]. Joghataei et al. cultured BMSCs and Schwann
cells (SCs) and then transplanted them into an experimental
model of spinal cord injury. Findings of their study showed
that these cells promoted functional recovery and caused
axonal regeneration in the injured animals. They proposed
that BMSCs and SCs secreted neurotrophic factors which
resulted in functional recovery in these animals [49]. Munoz
et al. have reported that transplantation of BMSCs led to
increased neurogenesis in hippocampal cells [50]. Chen et
al. developed an experimental stroke model by occluding
the middle cerebral arteries. Following intravenous injec-
tion of BMSCs, they evaluated the level of neurogenesis,
apoptosis, and bFGF expression. Their findings showed that
BMSCs increased both neurogenesis and bFGF expression
and decreased apoptosis [51].
All of the abovementioned findings agree with the
results of the current study. We demonstrated that intra-
venous injection of BMSCs in an experimental model
of ischemia-reperfusion led to hippocampal cell survival,
reduction of apoptosis in these cells, and improvement
of functional recovery. It has been proposed that post-
ischemia-reperfusion injected BMSCs express neurotrophic
and growth factors which prevent neuronal apoptosis, result-
ing in neuron and glial cell survival, which lead to enhanced
behavioral recovery. These factors have provided a suitable
environment that promoted axonal growth and resulted in
locomotor recovery. BMSCs can improve vascularization
through the expression of VEGF leading to damaged neural
tissue repair [52].
Our findings have suggested that administration of
BMSCs one week after ischemia-reperfusion can reduce
hippocampal cell apoptosis in the ratmodel.This has resulted
in improved locomotor function and it may be employed as
a useful method for treatment of human cerebral ischemia.
The BMSCs have a number of advantages compared to
other cells commonly used in cell therapy; they can be
easily isolated and cultured and their transplantation is safe
without immunological reactions. Indeed, further studies are
required for the development of this method as a treatment
for strokes in humans.
5. Conclusion
In this study, the results of intravenous administration of
BMSCs in an animal model of ischemia-reperfusion revealed
considerable reduction of apoptosis in hippocampal cells,
along with neuron survival and functional recovery.Thismay
be a beneficial treatment method for ischemic injuries. It
has been proposed that post-ischemia-reperfusion injected
BMSCs express neurotrophic and growth factors which
prevent neuronal apoptosis, resulting in neuron and glial cell
survival, which lead to enhanced behavioral recovery. These
factors have provided a suitable environment that promoted
axonal growth and resulted in locomotor recovery.
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